Amendments To the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

41. (previously presented) A compound of formula Ib, or a pharmaceutically acceptable salt or individual diastereomer thereof:



Ib

wherein:
the dashed line represents a single or a double bond;

Z is selected from:

C, N, and -O-, wherein when Z is N, R^4 is absent and n is 1; and when Z is -O-, both R^3 and R^4 are absent, and n is 1; and when Z is C, n is 0, 1, or 2;

X is -CONH-;

R^2 is -CH_2-phenyl,

wherein phenyl is unsubstituted or substituted with 1-3 substituents independently selected from:

(a) halo,
(b) trifluoromethyl,
(c) trifluoromethoxy,
(d) hydroxy,
(e) C_1-3alkyl,
(f) -O-C_1-3alkyl, and
(h) -CO_2H;

R^3 is selected from H and -(C_{0-6}alkyl)-phenyl,

wherein alkyl is unsubstituted or substituted with 1-5 substituents independently selected from:

(a) halo,
(b) hydroxy,
(c) -O-C_{1-3}alkyl, and
(d) trifluoromethyl,

and wherein phenyl is unsubstituted or substituted with 1-5 substituents independently selected from:

(a) halo,
(b) trifluoromethyl,
(c) hydroxy,
(d) C_{1-3}alkyl,
(e) -O-C_{1-3}alkyl,
(f) -CO_2R^9,
(g) -CN,
(h) -NR^9R^{10}, and
(i) -$CONR^9R^{10}$;

R^4 is selected from the group consisting of:

(a) hydrogen,
(b) hydroxy,
(c) C_{1-6}alkyl,
(d) C_{1-6}alkyl-hydroxy,
(e) -O-C_{1-3}alkyl,
(f) -CO_2R^9,
(g) -$CONR^9R^{10}$, and
(h) -CN;

R^9 and R^{10} are each independently selected from H and C_{1-6}alkyl;

R^5 and R^6 are each independently selected from the group consisting of:

(a) hydrogen,

(b) hydroxy,

(c) $-CH_3$,

(d) $-O-CH_3$, and

(e) oxo; or alternatively

R^6 is H, and R^5 is defined in the Table below for compounds of formula I in which R^3, R^4, Z, and n are as defined in the Table:



I

wherein each compound of formula I has the substituents shown in the table:

Ex.	R^3	R^4	R^5	n	Z
54	H	H	Ph	0	C
55	H	H	$PhCH_2$	1	C
57	H	H	NHBoc	0	C
59	H	H	o-MePh	0	C
60	H	$HOCH_2$	Ph	0	C
62	H	H	Ph	1	C
64	H	H	Ph	1	C
67	H	H	CO_2Me	1	C;

and

R^{11} and R^{12} are H; and

m is an integer selected from 1 and 2.

42. (previously presented) The compound of Claim 41 having the formula Id:



Id

or a pharmaceutically acceptable salt or individual diastereomer thereof.

43. (previously presented) The compound of Claim 41 of formula If:



If

or a pharmaceutically acceptable salt or individual diastereomer thereof.

44. (previously presented) The compound of Claim 41 wherein Z is -C- or -N-.

45. (previously presented) The compound of Claim 41 wherein n is 0 or 1.

46. (previously presented) The compound of Claim 41 wherein m is 1.

47. (previously presented) The compound of Claim 41 wherein R^2 is selected from:

(1) $-CH_2$-(phenyl),
(2) $-CH_2$-(4-bromophenyl),
(3) $-CH_2$-(3-chlorophenyl),
(4) $-CH_2$-(3,5-difluorophenyl),
(5) $-CH_2$-((2-trifluoromethyl)phenyl),
(6) $-CH_2$-((3-trifluoromethyl)phenyl),

(7) -CH_2-((4-trifluoromethyl)phenyl),
(8) -CH_2-((3-trifluoromethoxy)phenyl),
(9) -CH_2-((3-trifluoromethoxy-5-methoxy)phenyl),
(10) -CH_2-((3,5-bis-trifluoromethyl)phenyl), and
(11) -CH_2-((3-fluoro-5-trifluoromethyl)phenyl),

48. (previously presented) The compound of Claim 41 wherein R^2 is -CH_2-((3,5-bis-trifluoromethyl)phenyl).

49. (previously presented) The compound of Claim 41 wherein R^3 is hydrogen or phenyl,
wherein the phenyl is unsubstituted or substituted with 1-5 substituents independently selected from:

(a) halo,
(b) trifluoromethyl,
(c) hydroxy,
(d) C_{1-3}alkyl,
(e) -O-C_{1-3}alkyl,
(f) -CO_2R^9,
(g) -CN,
(h) -NR^9R^{10}, and
(i) -$CONR^9R^{10}$.

50. (previously presented) The compound of Claim 41 wherein R^3 is hydrogen or phenyl, where phenyl is unsubstituted or substituted with 1-3 substituents independently selected from:

(a) halo,
(c) hydroxy,
(d) C_{1-3}alkyl,
(e) -O-C_{1-3}alkyl, and
(f) -CO_2R^9.

51. (previously presented) The compound of Claim 41 wherein R^3 is phenyl or para-fluorophenyl.

52. (previously presented) The compound of Claim 41 wherein R^4 is selected from:

(a) hydrogen,
(b) hydroxy,
(c) $-CO_2H$,
(d) $-CO_2C_{1-6}$alkyl, and
(e) -CN.

53. (previously presented) The compound of Claim 41 which is selected from the group of the following compounds, or a pharmaceutically acceptable salt thereof:



Ex. 52



Ex. 78

54. (currently amended) The compound of Claim 41, or a pharmaceutically acceptable salt or individual diastereomer thereof, selected from compounds having formula I ~~and II~~ below:



I

wherein each compound of formula I has the substituents shown in the table:

Ex.	R^3	R^4	R^5	n	Z
53	H	H	H	0	C
54	H	H	Ph	0	C
55	H	H	$PhCH_2$	1	C
56	H	H	OH	1	C
57	H	H	NHBoc	0	C
58	H	H	OH	0	C
59	H	H	o-MePh	0	C
60	H	$HOCH_2$	Ph	0	C

61	$PhCH_2CH_2CH_2$	OH	H	1	C
62	H	H	Ph	1	C
63	Ph	H	H	1	C
64	H	H	Ph	1	C
65	H	NHBoc	H	1	C
66	H	CO_2Me	H	1	C
67	H	H	CO_2Me	1	C
68	CO_2Me	None	H	1	N
69	Ph	None	H	1	N
70	None	None	H	1	O
71	H	H	H	2	C.

and

55. (previously presented) A pharmaceutical composition which comprises an inert carrier and the compound of Claim 41.

56. (previously presented) A method for modulation of CCR2 receptor activity in a mammal in need thereof which comprises the administration of an effective amount of the compound of Claim 41.

57 – 59. Canceled